Advertisement

Medical Oncology

, 35:141 | Cite as

Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study

  • Tarcila Santos Datoguia
  • Elvira Deolinda Rodrigues Pereira Velloso
  • Ricardo Helman
  • Juliane Garcez Musacchio
  • Marco Aurélio Salvino
  • Rodolfo Almeida Soares
  • Marcia Higashi
  • Adriana Valente Fadel
  • Rodrigo Santucci Alves e Silva
  • Nelson Hamerschlak
  • Fabio Pires de Souza Santos
  • Paulo Vidal Campregher
Original Paper
  • 101 Downloads

Abstract

Prognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML. We have analysed outcomes in 65 AML cases (median age of 54 years, range 18–82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis. We classified patients as favorable (N = 13), intermediate-1 (N = 25), intermediate-2 (N = 15), or adverse risk (N = 9). Bone marrow transplantation (BMT) was performed in 13 patients (21%). Median follow-up was 12 months. The median overall survival (OS) for all patients was 12.4 months. Median OS was 19.8, 12.4, 10.1, and 10.4 months (p = 0.24) for patients in the favorable, intermediate-1, intermediate-2, and adverse groups, respectively. Among patients receiving BMT, median OS was 26.8 months. The ELN is a valuable tool for prognostic stratification of AML patients treated in Brazil. Nevertheless, its usefulness is limited when compared to data from developed countries.

Keywords

Acute myeloid leukemia Risk stratification Stem cell transplantation Survival 

Notes

Compliance with ethical standards

Conflict of interest

All authors declared that they have no competing interest.

References

  1. 1.
    Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa. Incidência de câncer no Brasil. 2016. http://www.inca.gov.br/estimativa/2016. Accessed 6 Sept 2017.
  2. 2.
    Helman R, Santos FP, Simões B, Atta EH, Callera F, Dobbin Jde A, et al. Acute myeloid leukemia: update in diagnosis and treatment in Brazil. Einstein (Sao Paulo). 2011;9(2):179–83.CrossRefGoogle Scholar
  3. 3.
    Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74.CrossRefGoogle Scholar
  4. 4.
    Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30(36):4515–23.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Haferlach C, Rieder H, Lillington DM, Dastugue, Hagemeijer A, Harbott J, et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer. 2007;46(5):494–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Shaffer LG, McGowan-Jordan J, Schmid M. ISCN 2013: an international system for human cytogenetic nomenclature. Seattle: Karger; 2013.Google Scholar
  7. 7.
    Machado LE, Pinho JR, Sitnik R, Muto NH, Velloso ED, Petroni RC, et al. The detection of KIT mutations in acute myeloid leukemia. Einstein (Sao Paulo). 2012;10(3):286–91.CrossRefGoogle Scholar
  8. 8.
    Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Chen W, Xie H, Wang H, Chen L, Sun Y, Chen Z, et al. Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. PLoS ONE. 2016;11(1):e0146614.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Benicio MTL, Ribeiro AFT, Américo AD, Furtado FM, Glória AB, Lima AS, et al. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle- income countries (LMIC): A Brazilian experience. Leuk Res. 2017;60:109–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Lima AS, de Mello MR, Fernandes E, Bezerra MF, Oliveira MM, Duarte BK, et al. Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting. Blood. 2015;126(15):1863–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Alpermann T, Kern W, Schnittger S, Schmid C, Kreuzer KA, Serve H, et al. Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. Leuk Res. 2013;37(2):197–200.CrossRefPubMedGoogle Scholar
  14. 14.
    Fagundes EM, Rocha V, Glória AB, Clementino NC, Quintão JS, Guimarães JP, et al. De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center. Leuk Lymphoma. 2006;47(8):1557–64.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Tarcila Santos Datoguia
    • 1
  • Elvira Deolinda Rodrigues Pereira Velloso
    • 1
  • Ricardo Helman
    • 1
  • Juliane Garcez Musacchio
    • 2
  • Marco Aurélio Salvino
    • 3
  • Rodolfo Almeida Soares
    • 4
  • Marcia Higashi
    • 5
  • Adriana Valente Fadel
    • 6
  • Rodrigo Santucci Alves e Silva
    • 1
  • Nelson Hamerschlak
    • 1
  • Fabio Pires de Souza Santos
    • 1
  • Paulo Vidal Campregher
    • 1
    • 7
  1. 1.Centro de Pesquisa ClínicaInstituto Israelita de Ensino e Pesquisa Albert EinsteinSão PauloBrazil
  2. 2.Centro de Oncologia IntegradoHospital Quinta D’OrRio de JaneiroBrazil
  3. 3.Complexo Hospitalar Universitário Professor Edgard Santos (HUPES)Universidade Federal da Bahia (UFBA)SalvadorBrazil
  4. 4.Universidade Federal do Rio Grande do Norte (UFRN)NatalBrazil
  5. 5.Hospital Amaral CarvalhoJaúBrazil
  6. 6.Hospital das Clínicas da Faculdade de Medicina de BotucatuBotucatuBrazil
  7. 7.Centro de Pesquisa ClínicaInstituto Israelita de Ensino e Pesquisa Albert EinsteinSão PauloBrazil

Personalised recommendations